ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ARDX vs AVBP // REVENUE GROWTH (YOY)

Ardelyx Inc. (NASDAQ) VS. ArriVent BioPharma Inc. (NASDAQ) • 15-METRIC TALLY: ARDX 4 — AVBP 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARDX VS. AVBP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ARDX AVBP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 90.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.70% -35.00% +2.30 ARDX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -5.69% -20.42% +14.73 ARDX /fcf-yield <GO>
Operating Margin -10.10% — — TIE /operating-margins <GO>
Net Profit Margin -15.20% — — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE 22.10% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 ARDX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.1 36.9 +5.20 ARDX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $772.5M $786.5M -$14.0M AVBP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ARDX REV AVBP REV ARDX GROSS % AVBP GROSS % ARDX FCF AVBP FCF
FY 2025 $407.3M $0 90.3% — -$44.0M -$160.6M
FY 2024 $333.6M $0 84.8% — -$45.8M -$70.2M
FY 2023 $124.5M $0 — — -$89.7M -$55.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARDX // BETA —
AVBP // BETA —